Compare Stocks

→ Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed! (From Priority Gold) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALT Altimmune	$7.29 +1.3%	$9.31	$2.09 ▼ $14.84	$516.79M	0.05	5.29 million shs	274,430 shs
AMT American Tower	$174.77 +1.1%	$190.60	$154.58 ▼ $219.10	$81.50B	0.67	2.40 million shs	214,432 shs
DIM WisdomTree International MidCap Dividend Fund	$61.15 +0.7%	$61.55	$52.87 ▼ $63.06	$131.47M	0.87	5,111 shs	1,404 shs

7 Energy Stocks to Buy and Hold Forever

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALT Altimmune	+1.69%	+4.50%	-16.76%	-22.83%	+37.93%
AMT American Tower	-0.22%	+1.15%	-10.89%	-12.33%	-13.67%
DIM WisdomTree International MidCap Dividend Fund	-0.74%	+0.96%	-2.99%	+1.30%	+2.26%

These AI trades triggered this morning (545% return) (Ad)

If you think a market crash is possible in 2024, I don't know why you're not using this yet.

Click Here To Get Your Free Copy

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALT Altimmune	1.3698 of 5 stars	3.3	1.0	0.0	0.0	3.1	1.7	0.0
AMT American Tower	4.9831 of 5 stars	4.4	5.0	2.5	3.1	2.8	2.5	1.9
DIM WisdomTree International MidCap Dividend Fund	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALT Altimmune	2.67	Moderate Buy	$15.00	105.76% Upside
AMT American Tower	2.82	Moderate Buy	$217.36	24.37% Upside
DIM WisdomTree International MidCap Dividend Fund	0.00	N/A	N/A	N/A

Current Analyst Ratings

Latest DIM, ADR, AMT, and ALT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/15/2024	AMT American Tower	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$183.00 ➝ $196.00
4/8/2024	AMT American Tower	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral	$205.00
4/1/2024	ALT Altimmune	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$15.00 ➝ $12.00
3/28/2024	ALT Altimmune	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
3/5/2024	AMT American Tower	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$224.00 ➝ $234.00
2/28/2024	AMT American Tower	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$235.00 ➝ $228.00
2/28/2024	AMT American Tower	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$236.00 ➝ $230.00
2/13/2024	ALT Altimmune	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00

(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALT Altimmune	$430K	1,201.83	N/A	N/A	$2.75 per share	2.65
AMT American Tower	$11.14B	7.31	$9.99 per share	17.50	$23.30 per share	7.50
DIM WisdomTree International MidCap Dividend Fund	N/A	N/A	N/A	N/A	N/A	N/A

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALT Altimmune	-$88.45M	-$1.65	N/A	N/A	N/A	-20,780.75%	-44.77%	-40.72%	5/9/2024 (Estimated)
AMT American Tower	$1.48B	$3.18	54.96	16.94	1.37	13.31%	12.80%	2.24%	4/30/2024 (Confirmed)
DIM WisdomTree International MidCap Dividend Fund	N/A	N/A	9.21	∞	N/A	N/A	N/A	N/A	N/A

Latest DIM, ADR, AMT, and ALT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
4/30/2024	N/A	AMT American Tower	$2.45	N/A	-$2.45	N/A	N/A	N/A
3/27/2024	Q4 2023	ALT Altimmune	-$0.35	-$0.33	+$0.02	-$0.12	N/A	$0.04 million
2/27/2024	12/31/2023	AMT American Tower	$2.10	$0.94	-$1.16	$0.18	$2.74 billion	$2.79 billion

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALT Altimmune	N/A	N/A	N/A	N/A	N/A
AMT American Tower	$6.48	3.71%	+12.50%	203.77%	N/A
DIM WisdomTree International MidCap Dividend Fund	$2.19	3.58%	N/A	N/A	N/A

Latest DIM, ADR, AMT, and ALT Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
3/14/2024	AMT American Tower	quarterly	$1.62	3.3%	4/11/2024	4/12/2024	4/26/2024

(Data available from 1/1/2013 forward)

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALT Altimmune	N/A	17.26	17.26
AMT American Tower	3.29	0.69	0.69
DIM WisdomTree International MidCap Dividend Fund	N/A	N/A	N/A

Ownership

Institutional Ownership

Company	Institutional Ownership
ALT Altimmune	78.05%
AMT American Tower	92.69%
DIM WisdomTree International MidCap Dividend Fund	N/A

Insider Ownership

Company	Insider Ownership
ALT Altimmune	4.10%
AMT American Tower	0.24%
DIM WisdomTree International MidCap Dividend Fund	N/A

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
ALT Altimmune	59	70.89 million	67.99 million	Optionable
AMT American Tower	5,643	466.35 million	465.23 million	Optionable
DIM WisdomTree International MidCap Dividend Fund	N/A	2.15 million	N/A	Not Optionable

DIM, ADR, AMT, and ALT Headlines

Source	Headline
	WisdomTree International MidCap Dividend Fund declares quarterly distribution of $0.1100 msn.com - March 27 at 9:58 AM
	Largecap vs Midcap vs Smallcap MFs: Which mutual fund should risk-averse investor choose businesstoday.in - February 20 at 2:39 PM
	EZM WisdomTree U.S. MidCap Earnings Fund ETF seekingalpha.com - December 21 at 8:34 AM
	WisdomTree Announces Changes to ETF Registered Products benzinga.com - September 19 at 4:34 PM
	SRH ALSTERRESEARCH AG Maintains Traton SE (8TRA) Buy Recommendation msn.com - April 22 at 8:02 AM
	BANCO SANTANDER Maintains Verallia (VRLA) Outperform Recommendation msn.com - April 21 at 8:53 PM
	WisdomTree International Multifactor Fund declares quarterly distribution of $0.1966 msn.com - December 23 at 6:17 PM
	WisdomTree U.S. MidCap Dividend Fund declares monthly distribution of $0.1959 msn.com - December 23 at 1:16 PM
	Redsun Properties Group Ltd. wsj.com - August 20 at 7:22 PM
	Jiayuan International Group Ltd. wsj.com - August 16 at 7:07 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

3 Value Stocks Too Small For Buffett’s Portfolio
March 28, 2024 12:16 PM
View 3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Alphabet and Microsoft push Wall Street toward its first winning week in a month
April 26, 2024 3:21 AM
View Stock market today: Alphabet and Microsoft push Wall Street toward its first winning week in a month
Caterpillar’s Market Reset Isn’t Over: Get Ready for Lower Prices
April 25, 2024 10:36 AM
View Caterpillar’s Market Reset Isn’t Over: Get Ready for Lower Prices
Foot Locker Builds Up Another Head of Steam; Gains Imminent
March 28, 2024 10:58 AM
View Foot Locker Builds Up Another Head of Steam; Gains Imminent
Can Altimmune get its GLP-1 Drug to Market Before Cash Rush Out?
April 9, 2024 6:07 AM
View Can Altimmune get its GLP-1 Drug to Market Before Cash Rush Out?

All Headlines

Company Descriptions

Altimmune

NASDAQ:ALT

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.

American Tower

NYSE:AMT

American Tower, one of the largest global REITs, is a leading independent owner, operator and developer of multitenant communications real estate with a portfolio of over 224,000 communications sites and a highly interconnected footprint of U.S. data center facilities.

WisdomTree International MidCap Dividend Fund

NYSEARCA:DIM

WisdomTree International MidCap Dividend Fund (the Fund) seeks investment results that closely correspond to the price and yield performance of the WisdomTree International MidCap Dividend Index (the Index). The Index is a fundamentally weighted index that measures the performance of the mid-capitalization segment of the dividend-paying market in the industrialized world outside the United States and Canada. The Index consists of companies that compose the top 75% of the market capitalization of the WisdomTree DEFA Index after the 300 largest companies have been removed. Companies are weighted in the Index based on annual cash dividends paid. The Fund's investment advisor is WisdomTree Asset Management, Inc., a wholly owned subsidiary of WisdomTree Investments, Inc. Its sub-advisor is Mellon Capital Management Corporation.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial